Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Dexmedetomidin eller Clonidininfusion til forebyggelse af delirium efter åben hjertekirurgi (ALPHA2PREVENT)

16. november 2026 opdateret af: Bjørn Erik Neerland, MD, Oslo University Hospital

Alfa 2 adrenerge receptoragonister til forebyggelse af delirium og kognitiv tilbagegang efter åben hjertekirurgi (ALPHA2PREVENT): Randomiseret kontrolleret forsøg.

A parallel-group treatment, five-centre, participant and investigator masked, three-arm study to assess the safety and effectiveness of dexmedetomidine or clonidine infusion compared to placebo for the prevention of delirium and cognitive decline in male and female participants aged 70+ scheduled for open heart surgery.

Studieoversigt

Status

Aktiv, ikke rekrutterende

Betingelser

Intervention / Behandling

Detaljeret beskrivelse

Delirium is a major public health concern without therapeutic options. It is an acute disturbance of attention and cognition, precipitated by an acute somatic condition. Delirious patients are often subject to off-label treatment with psychotropic drugs that have dubious effects.

The intravenous alpha-2-adrenergic receptor agonist dexmedetomidine, attenuating sympathetic nervous system activity, shows promise as treatment for delirium, but its use is limited to intensive care units (ICU). Its long-term cognitive effects are unknown. Clonidine is a pharmacodynamically similar drug that can be given orally and has been used for decades as an antihypertensive agent, but is else sparsely studied.

ALPHA2PREVENT will be a three-armed randomised controlled trial to study 1) whether repurposing of clonidine can represent a novel treatment option for delirium, and 2) the possible effects of both dexmedetomidine and clonidine on long-term cognitive trajectories, motor activity patterns, patient rated outcome measures and biomarkers of neuronal injury.

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

900

Fase

  • Fase 4

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

      • Bergen, Norge
        • Haukeland University Hospital
      • Oslo, Norge
        • Oslo University Hospital Ullevål
      • Oslo, Norge
        • Oslo University Hospital Rikshospitalet
      • Tromsø, Norge
        • University Hospital of North Norway
      • Trondheim, Norge
        • St Olav University Hospital

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

70 år og ældre (Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

Participants are eligible to be included in the study only if all of the following criteria apply:

  1. Participant must be ≥70 years old at the time of signing the informed consent.

  2. Participant must be accepted for cardiac surgery with cardiopulmonary bypass. The surgical procedures may constitute 1) coronary bypass grafting, 2) tricuspid, mitral, or aortic valve replacement or repair, 3) surgery on the ascending aorta, and 4) the combination any of these procedures.

  3. Participant must be capable of giving signed informed consent.

    Exclusion Criteria:

    Participants are excluded from the study if any of the following criteria apply:

  4. Preoperative delirium

  5. Known hypersensitivity to the active ingredient or components of the product

  6. Bradycardia due to sick-sinus-syndrome, 2nd or 3rd degree AV-block (if not treated with pacemaker) or any other reason causing HR <50 bpm at time of inclusion

  7. Uncontrolled hypotension

  8. Ischemic stroke or transitory ischemic attack the last month or critical peripheral ischemia

  9. Acute coronary syndrome last 24 hours. Acute coronary syndrome is defined according to international guidelines

  10. Left ventricular ejection fraction < 40%

  11. Severe renal impairment (estimated GFR <20ml/min) or expected requirement for renal replacement therapy

  12. Severe hepatic dysfunction (liver enzyme three times the upper limit of normal together with a serum albumin concentration below the normal reference limit)

  13. Reduced peripheral autonomous activity (e.g. spinal cord injury)

  14. Current use of tricyclic antidepressants, monoamine reuptake inhibitors or ciclosporin

  15. Endocarditis or sepsis

  16. Pheochromocytoma

  17. Planned deep hypothermia and circulatory arrest

  18. Emergency surgery, defined as less than 24 hours from admission to surgery

  19. Previously included in this study

  20. Not speaking or reading Norwegian

  21. Any other condition as evaluated by the treating physician

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Forebyggelse
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Firedobbelt

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: Dexmedetomidine (D)

Continuous intravenous infusion of dexmedetomidine 0.4 μg/kg/hour from the start of cardiopulmonary bypass and during surgery, followed by 0.2 μg/kg/hour until discharge from the ICU or 24 hours postoperatively, whichever happens first.

Continous intravenous infusion

Andre navne:
  • Precedex
  • Dexdor
  • N05C M18
Eksperimentel: Clonidine (C)

Continuous intravenous infusion of clonidine 0.4 μg/kg/hour from the start of cardiopulmonary bypass and during surgery, followed by 0.2 μg/kg/hour until discharge from the ICU or 24 hours postoperatively, whichever happens first.

Continous intravenous infusion

Andre navne:
  • Catapresan
  • Catapressan
  • N02C X02
Placebo komparator: Placebo (P)

Continuous intravenous infusion of saline 0.4 μg/kg/hour from the start of cardiopulmonary bypass and during surgery, followed by 0.2 μg/kg/hour until discharge from the ICU or 24 hours postoperatively, whichever happens first.

Continous intravenous infusion NaCl

Andre navne:
  • Saltvand
  • NaCl 9 mg/ml

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Postoperative delirium
Tidsramme: Up to 7 days

Cumulative incidence of postoperative delirium, as diagnosed according to Diagnostic and Statistical Manual of Mental Disorders, 5th edition (DSM-5) criteria

Up to 7 days

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Incidence of coma
Tidsramme: Up to 7 days

Incidence of coma, as measured by Richmond Agitation Sedation Scale (-5 to +5)

Up to 7 days
Incidence of death, coma or postoperative delirium
Tidsramme: Up to 7 days

Incidence of death, coma or postoperative delirium, as described above

Up to 7 days
Number of delirium days postoperatively
Tidsramme: Up to 7 days

Number of delirium days postoperatively, as diagnosed according to DSM-5 criteria

Up to 7 days
Delirium severity
Tidsramme: Up to 7 days

Delirium severity, as measured by Confusion Assessment Method for Intensive Care Units-7 (CAM-ICU)-7

Up to 7 days
Motor activity patterns
Tidsramme: 6 months

Motor activity patterns, assessed with body worn accelerometers

6 months
Change in cognitive function between inclusion and after 1 and 6 months
Tidsramme: 6 months

Change in cognitive function between inclusion and after 1 and 6 months, as graded by Montreal Cognitive Assessment (MoCA), 10-words memory task from The Consortium Establish a Registry for Alzheimer's Disease (CERAD), digit span tests, Trail making tests (TMT) A and B, semantic and phonemic verbal fluency, and measured repeatedly preoperatively and 1 and 6 months after surgery

6 months
Change in patient rated health status between inclusion and after 1 and 6 months
Tidsramme: 6 months

Change in patient rated health status between inclusion and after 1 and 6 months, as assessed by the EQ-5D-5L questionnaire preoperatively and 1 and 6 months postoperatively

6 months
Serum concentrations of NFL and p-tau181
Tidsramme: 5 days postoperatively

Comparison to inclusion of serum concentrations of neurofilament light (NFL) and p-tau181 1, 3 and 5 days postoperatively

5 days postoperatively
Estimate associations between frailty and the other endpoints
Tidsramme: 6 months

Estimate associations between frailty and the other endpoints, as described above

6 months
Safety and tolerability
Tidsramme: 6 months

Safety and tolerability as determined by the numbers of Adverse Events (AEs), serious AEs (SAEs) and suspected unexpected serious adverse reactions (SUSARs), and vital signs; blood pressure (BP), heart rate (HR), peripheral oxygen saturation (SpO2) postoperatively

6 months
Interaction between preoperative frailty and treatment on delirium and the other endpoints
Tidsramme: 6 months

Interaction between preoperative frailty and treatment on delirium and the other endpoints, as described above

6 months
Change in frailty status between inclusion and after 1 and 6 months
Tidsramme: 6 months

Change in frailty status between inclusion and after 1 and 6 months, as graded by the frailty index (FI) and essential frailty toolset (EFT) (section 8.1.3), and measured repeatedly preoperatively and 1 and 6 months after surgery

6 months
Comparison of change in frailty status between inclusion and after 1 and 6 months
Tidsramme: 6 months

Comparison of change in frailty status between inclusion and after 1 and 6 months (as described above) between patients with or without postoperative delirium.

6 months

Andre resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Additional biomarkers
Tidsramme: 5 days postoperatively

Additional biomarkers of neural injury, inflammation or neurotransmission may be explored

5 days postoperatively

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Samarbejdspartnere

Efterforskere

  • Ledende efterforsker: Bjørn Erik Neerland, PhD, Oslo University Hospital

Publikationer og nyttige links

Den person, der er ansvarlig for at indtaste oplysninger om undersøgelsen, leverer frivilligt disse publikationer. Disse kan handle om alt relateret til undersøgelsen.

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

17. januar 2022

Primær færdiggørelse (Faktiske)

31. juli 2026

Studieafslutning (Anslået)

1. januar 2027

Datoer for studieregistrering

Først indsendt

21. august 2021

Først indsendt, der opfyldte QC-kriterier

25. august 2021

Først opslået (Faktiske)

31. august 2021

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

19. november 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

16. november 2026

Sidst verificeret

1. november 2026

Mere information

Begreber relateret til denne undersøgelse

Andre undersøgelses-id-numre

  • 2021-001645-12
  • 2021-001645-12 (EudraCT nummer)

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

JA

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

produkt fremstillet i og eksporteret fra U.S.A.

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .